IGM Biosciences (IGMS) Competitors

Olema Pharmaceuticals (NASDAQ:OLMA) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Does the MarketBeat Community believe in OLMA or IGMS?

IGM Biosciences received 33 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 72.22% of users gave Olema Pharmaceuticals an outperform vote while only 46.75% of users gave IGM Biosciences an outperform vote.

Company	Underperform	Outperform
Olema Pharmaceuticals	Outperform Votes 39 72.22%	Underperform Votes 15 27.78%
IGM Biosciences	Outperform Votes 72 46.75%	Underperform Votes 82 53.25%

Is OLMA or IGMS more profitable?

Olema Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. Olema Pharmaceuticals' return on equity of -53.56% beat IGM Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-53.56%	-47.86%
IGM Biosciences	-7,534.03%	-155.42%	-61.04%

Which has better earnings and valuation, OLMA or IGMS?

Olema Pharmaceuticals has higher earnings, but lower revenue than IGM Biosciences. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$96.65M	-$2.01	-2.04
IGM Biosciences	$2.68M	28.32	-$246.42M	-$3.27	-0.39

Do institutionals & insiders have more ownership in OLMA or IGMS?

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 16.4% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 57.0% of IGM Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the media refer more to OLMA or IGMS?

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 3 articles in the media. IGM Biosciences' average media sentiment score of 0.70 beat Olema Pharmaceuticals' score of -0.03 indicating that IGM Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IGM Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer OLMA or IGMS?

Olema Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 496.54%. IGM Biosciences has a consensus price target of $5.50, indicating a potential upside of 333.07%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than IGM Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
IGM Biosciences	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90

Which has more volatility & risk, OLMA or IGMS?

Olema Pharmaceuticals has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Summary

Olema Pharmaceuticals beats IGM Biosciences on 11 of the 16 factors compared between the two stocks.